NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron

PURPOSE: Antiemetic guidelines recommend co-administration of targeted prophylactic medications inhibiting molecular pathways involved in emesis. NEPA is a fixed oral combination of a new NK(1) receptor antagonist (RA), netupitant (NETU 300 mg), and palonosetron (PALO 0.50 mg), a pharmacologically d...

Descripción completa

Detalles Bibliográficos
Autores principales: Aapro, Matti, Karthaus, Meinolf, Schwartzberg, Lee, Bondarenko, Igor, Sarosiek, Tomasz, Oprean, Cristina, Cardona-Huerta, Servando, Hansen, Vincent, Rossi, Giorgia, Rizzi, Giada, Borroni, Maria Elisa, Rugo, Hope
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321708/
https://www.ncbi.nlm.nih.gov/pubmed/27885469
http://dx.doi.org/10.1007/s00520-016-3502-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321708/
https://www.ncbi.nlm.nih.gov/pubmed/27885469
http://dx.doi.org/10.1007/s00520-016-3502-x

Ejemplares similares